EQS Group-Ad-hoc: Medartis Holding AG / Key word(s): AGMEGM/Personnel 
Medartis Holding AG : Annual General Meeting approves all proposals of the Board of Directors and elects Marco Gadola 
as the new Chairman of the Board of Directors 
23-Apr-2021 / 17:45 CET/CEST 
Release of an ad hoc announcement pursuant to Art. 53 KR 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
Medartis Holding AG 
Hochbergerstrasse 60E 
CH-4057 Basel 
PRESS RELEASE 
Annual General Meeting approves all proposals of the Board of Directors and elects Marco Gadola as the new Chairman of 
the Board of Directors 
Basel, Switzerland, 23 April 2021 - At today's Annual General Meeting of Medartis Holding AG (SIX: MED), shareholders 
approved all the proposals of the Board of Directors by a large majority and elected Marco Gadola as the new Chairman 
of the Board of Directors. He succeeds Dr. h.c. Thomas Straumann, who will assume the role of Vice Chairman. 
At today's Annual General Meeting of Medartis Holding AG, which took place without shareholders being physically 
present at the event due to the Covid-19 situation, 9'426'464 shares were represented, corresponding to 80% of total 
share capital. 
All existing members of the Board of Directors - Dr. h.c. Thomas Straumann, Marco Gadola, Dominik Ellenrieder, Dr. Jürg 
Greuter, Dr. med. Daniel Herren, Roland Hess, Willi Miesch and Damien Tappy - were re-elected for a further term of 
office of one year. Marco Gadola was newly elected as Chairman of the Board of Directors for the next one-year term. 
Dr. h.c. Thomas Straumann, who founded Medartis in 1997, stated: "After 23 years, I am very pleased to place the 
chairmanship of the Board of Directors on a very solid basis in the capable hands of Marco Gadola. I wish him all the 
best and every success as Chairman of the Board of Directors of our company. I personally remain committed to Medartis 
over the long term as a significant shareholder and as Vice Chairman of the Board of Directors." 
Marco Gadola, the new Chairman of the Board of Directors of Medartis, commented: "I would like to thank shareholders 
for electing me and for the trust they have placed in me. In my role as Chairman, I will work with the Board of 
Directors and the Executive Management Board to establish Medartis as a leading comprehensive solutions provider for 
the extremities and the head, with a broad international presence. I am also passionate about further evolving our 
strong corporate culture as an important component of Medartis' success." 
Shareholders further approved the Management Report, the Annual Financial Statements and the Consolidated Financial 
Statements 2020. A dividend will not be distributed for the 2020 financial year. In addition, shareholders granted 
discharge to the members of the Board of Directors for their activities during the 2020 financial year and approved the 
agenda items relating to compensation. 
More detailed information as well as the voting results for the individual agenda items can be found on Medartis' 
website at Investor & Media Relations or at the following link. 
The next Annual General Meeting will be held on 06 April 2022. 
Contact 
Patrick Christ 
Head Corporate Services 
Medartis Holding AG 
Phone: +41 61 633 34 70 
patrick.christ@medartis.com 
About Medartis 
Founded in 1997 and headquartered in Basel, Switzerland, Medartis is one of the world's leading manufacturers and 
providers of medical devices for surgical fixation of bone fractures for upper and lower extremities as well as for the 
craniomaxillofacial region. Medartis employs over 640 individuals across its 14 locations, with products offered in 
over 50 countries globally. Medartis is committed to providing surgeons and operating theatre personnel with the most 
innovative titanium implants and instruments as well as best in class service. For more information, please visit 
www.medartis.com. 
Disclaimer 
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Medartis 
Holding AG. This publication may contain certain forward-looking statements and assessments or intentions concerning 
the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause 
the actual results, financial condition, performance or achievements of the company to be materially different from 
those expressed or implied by such statements. Readers should therefore not place reliance on these statements, 
particularly not in connection with any contract or investment decision. The company disclaims any obligation to update 
these forward-looking statements, assessments or intentions. Further, neither the company nor any of its directors, 
officers, employees, agents, counsel or advisers nor any other person makes any representation or warranty, express or 
implied, as to, and accordingly no reliance should be placed on, the accuracy or completeness of the information 
contained herein or of the views given or implied. 
=---------------------------------------------------------------------------------------------------------------------- 
End of ad hoc announcement 
=---------------------------------------------------------------------------------------------------------------------- 
Language:     English 
Company:      Medartis Holding AG 
              Hochbergerstrasse 60E 
              4057 Basel 
              Switzerland 
Phone:        +41 61 633 34 34 
Fax:          +41 61 633 34 00 
E-mail:       info@medartis.com 
Internet:     www.medartis.com 
ISIN:         CH0386200239 
Valor:        38620023 
Listed:       SIX Swiss Exchange 
EQS News ID:  1187932 
 
End of Announcement EQS Group News Service 
=------------

1187932 23-Apr-2021 CET/CEST


 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1187932&application_name=news

(END) Dow Jones Newswires

April 23, 2021 11:47 ET (15:47 GMT)